Sirio launches postbiotic gummy using Cargill’s EpiCor
Sirio Pharma Co. Ltd. has announced the launch of a postbiotic gummy that features EpiCor, a postbiotic yeast fermentate ingredient from Cargill.
Gummy supplements. Image courtesy of Sirio Pharma.
Sirio Pharma Co. Ltd. has announced the launch of a postbiotic gummy that features EpiCor, a postbiotic yeast fermentate ingredient from Cargill that is backed by eight human and eight pre-clinical studies. The gummy, called BloomDays, targets immune health via the gut by delivering 500 mg of EpiCor per 2-gummy serving.
"We are truly excited to collaborate with Cargill – a global leader committed to nourishing the world in a safe, responsible, and sustainable way to introduce an exceptional product that combines our strengths in health and wellness innovation," said Sara Lesina, general manager Europe and Americas for Sirio, in a press release. "BloomDays represents a milestone in our commitment to collaborating with reputable ingredients suppliers to launch innovative and unique solutions for our customers, helping them win in the market. BloomDays not only tastes great and provides meaningful health benefits but also offers a unique value proposition.”
"We are excited to collaborate with Sirio as they make the health benefits of EpiCor available to more people through the introduction of their new, postbiotic gummy,” added Adam Hertell, global commercial director of dietary supplements for EpiCor. “With excellent stability properties, EpiCor offers the versatility and simplicity that pairs well with gummy manufacturing, making for a winning combination.”
The postbiotic gummy will make its official debut at Natural Product Expo West 2024, at the Anaheim Convention Center, taking place between March 14 and 16. Attendees will be able to taste BloomDays at booth #3905. Eventually, the product will be launched in Europe in the second half of 2024 at CHPI Milan.
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.
Survey finds a lack of enthusiasm about AI technology among food and beverage consumers
December 12th 2024The survey, commissioned by Ingredient Communications and conducted by SurveyGoo, found that 83% of respondent agreed that companies should declare on product labels when a product has been designed or manufactured with the assistance of AI technology.
